全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Lack of TEK Gene Mutation in Patients with Cutaneomucosal Venous Malformations from the North-Western Region of Algeria

DOI: 10.1155/2013/784789

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background. Venous malformations (VM) result from an error in vascular morphogenesis. The first gene suspected in their development is the TEK gene (tyrosine kinase, endothelial). Mutations of this gene have been identified in several Belgian families with a dominant form of the disease. Therefore, we investigated whether mutations in this TEK gene could explain the MV development in patients of families from Tlemcen region (north-western Algeria). Methods. Genomic DNA was extracted from leucocytes of ten patients. The search for mutations in all the 23 exons and in the 5′ and 3′ intronic sequences flanking the TEK gene was performed using PCR amplification and direct sequencing of amplified genomic DNA. Additionally, a search for somatic mutations of the gene TEK was performed on a biopsy of the venous malformation from one of the ten eligible patients. Results. The sequencing of the 23 exons of the TEK gene revealed neither germinal mutation in our ten patients nor somatic mutation in the tissue of the biopsy. Conclusion. The absence of mutation in the TEK gene in the population studied suggests that the TEK gene is not necessarily involved in the onset of VM; its association with these malformations may differ from one population to another. 1. Introduction Vascular malformations (VM) are benign vascular lesions that are described as structural congenital anomalies [1]. These lesions are always present at birth, but may not be visible until days, weeks, or even years after birth [2]. VM are classified according to the type of involved vessels, such as arterial, venous, lymphatic, capillary malformations, or a combination of different vessels [1–3]. VM result from an error in vascular morphogenesis [4]. They are present at birth and their growth is usually gradual and steady during the first year of life [3]. Their evolutionary peak is generally observed in adolescence or after a traumatic event [5]. Localized facial forms are present essentially on the lips, eyelids, and tongue [5, 6]. The extension of the gingival mucosa can result in bleeding, which can occur spontaneously and/or after certain dental procedures and treatments [7]. Some locations cause, by mass effect, skeletal deformities in the frontoorbital region with enophthalmos and maxillomandibular and dentoalveolar defects, with repercussions on the dental bite and open bite [5, 8]. An important lip deformity tends to make them incompetent. Likewise, giant VM of the tongue can cause permanent changes in normal dental occlusion [7, 8]. Additionally, superficial VM can lead to disfigurement,

References

[1]  R. G. Elluru, “Cutaneous vascular lesions,” Facial Plastic Surgery Clinics of North America, vol. 21, no. 1, pp. 111–126, 2013.
[2]  O. Enjolras, “Hemangiomes,” in Atlas des Hémangiomes et Malformations Vasculaires Superficielles, O. Enjolras, M. C. Riche, J. B. Mulliken, and J. J. Merland, Eds., pp. 17–54, Medsi McGraw-Hill, Paris, France, 1990.
[3]  F. Lemarchand-Venencien, “Classification of angiomas: hemangiomas and superficial vascular malformations,” Revue du Praticien, vol. 42, no. 16, pp. 1998–2004, 1992.
[4]  D. A. Marchuk, S. Srinivasan, T. L. Squire, and J. S. Zawistowski, “Vascular morphogenesis: tales of two syndromes,” Human Molecular Genetics, vol. 12, no. 1, pp. R97–R112, 2003.
[5]  J. Murthy, “Vascular anomalies,” Indian Journal of Plastic Surgery, vol. 38, no. 1, pp. 56–62, 2005.
[6]  G. T. Richter and A. B. Friedman, “Hemangiomas and vascular malformations: current theory and management,” International Journal of Pediatrics, vol. 2012, Article ID 645678, 10 pages, 2012.
[7]  A. Di Giovanni and L. Revelli, “Venous angiodysplasias with endoral manifestation. The problems of therapy,” Minerva stomatologica, vol. 45, no. 3, pp. 113–119, 1996.
[8]  L. B. Kaban and J. B. Mulliken, “Vascular anomalies of the maxillofacial region,” Journal of Oral and Maxillofacial Surgery, vol. 44, no. 3, pp. 203–213, 1986.
[9]  J. A. Werner, A. A. Dünne, B. J. Folz et al., “Current concepts in the classification, diagnosis and treatment of hemangiomas and vascular malformations of the head and neck,” European Archives of Oto-Rhino-Laryngology, vol. 258, no. 3, pp. 141–149, 2001.
[10]  D. Herbreteau, O. Enjolras, and M. C. Riché, “Superficial venous malformations,” Revue du Praticien, vol. 42, no. 16, pp. 2025–2030, 1992.
[11]  M. Vikkula, L. M. Boon, K. L. Carraway III et al., “Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2,” Cell, vol. 87, no. 7, pp. 1181–1190, 1996.
[12]  L. M. Boon, J. B. Mulliken, M. Vikkula et al., “Assignment of a locus for dominantly inherited venous malformations to chromosome 9p,” Human Molecular Genetics, vol. 3, no. 9, pp. 1583–1587, 1994.
[13]  V. Wouters, N. Limaye, M. Uebelhoer et al., “Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects,” European Journal of Human Genetics, vol. 18, no. 4, pp. 414–420, 2010.
[14]  N. Limaye, L. M. Boon, and M. Vikkula, “From germline towards somatic mutations in the pathophysiology of vascular anomalies,” Human Molecular Genetics, vol. 18, no. 1, pp. R65–R74, 2009.
[15]  B. Sari, M. Aribi, and B. Saari, “Effect of endogamy and consanguinity on the development of labial venous malformations in area of Tlemcen (West Algeria),” The Open Genomics Journal, vol. 1, pp. 1–5, 2008.
[16]  O. Enjolras, M. C. Riche, and J. J. Merland, “Superficial arterial and venous malformations: clinical features and complementary investigations,” Annales de Chirurgie Plastique et Esthetique, vol. 36, no. 4, pp. 271–278, 1991.
[17]  S. Rozen and H. Skaletsky, “Primer3 on the WWW for general users and for biologist programmers,” Methods in Molecular Biology, vol. 132, pp. 365–386, 2000.
[18]  T. Hubbard, D. Barker, E. Birney et al., “The Ensembl genome database project,” Nucleic Acids Research, vol. 30, no. 1, pp. 38–41, 2002.
[19]  D. J. Dumont, T. P. Yamaguchi, R. A. Conlon, J. Rossant, and M. L. Breitman, “Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors,” Oncogene, vol. 7, no. 8, pp. 1471–1480, 1992.
[20]  H. Schnurch and W. Risau, “Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage,” Development, vol. 119, no. 3, pp. 957–968, 1993.
[21]  T. N. Sato, Y. Qin, C. A. Kozak, and K. L. Audus, “Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 9355–9358, 1993.
[22]  D. J. Dumont, G. Gradwohl, G. H. Fong et al., “Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo,” Genes and Development, vol. 8, no. 16, pp. 1897–1909, 1994.
[23]  D. J. Dumont, G. H. Fong, M. C. Puri, G. Gradwohl, K. Alitalo, and M. L. Breitman, “Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development,” Developmental Dynamics, vol. 203, no. 1, pp. 80–92, 1995.
[24]  T. N. Sato, Y. Tozawa, U. Deutsch et al., “Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation,” Nature, vol. 376, no. 6535, pp. 70–74, 1995.
[25]  C. Suri, P. F. Jones, S. Patan et al., “Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis,” Cell, vol. 87, no. 7, pp. 1171–1180, 1996.
[26]  J. Partanen and D. J. Dumont, “Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development,” Current Topics in Microbiology and Immunology, vol. 237, pp. 159–172, 1999.
[27]  N. Jones, K. Iljin, D. J. Dumont, and K. Alitalo, “Tie receptors: new modulators of angiogenic and lymphangiogenic responses,” Nature Reviews Molecular Cell Biology, vol. 2, no. 4, pp. 257–267, 2001.
[28]  L. Eklund and B. R. Olsen, “Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling,” Experimental Cell Research, vol. 312, no. 5, pp. 630–641, 2006.
[29]  P. C. Maisonpierre, C. Suri, P. F. Jones et al., “Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis,” Science, vol. 277, no. 5322, pp. 55–60, 1997.
[30]  S. Loughna and T. N. Sato, “Angiopoietin and Tie signaling pathways in vascular development,” Matrix Biology, vol. 20, no. 5-6, pp. 319–325, 2001.
[31]  P. Saharinen, K. Kerkel?, N. Ekman et al., “Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2,” Journal of Cell Biology, vol. 169, no. 2, pp. 239–243, 2005.
[32]  H. T. Yuan, S. Venkatesha, B. Chan et al., “Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival,” FASEB Journal, vol. 21, no. 12, pp. 3171–3183, 2007.
[33]  D. M. Valenzuela, J. A. Griffiths, J. Rojas et al., “Angiopoietins 3 and 4: diverging gene counterparts in mice and humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 1904–1909, 1999.
[34]  I. Cascone, L. Napione, F. Maniero, G. Serini, and F. Bussolino, “Stable interaction between α5β1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1,” Journal of Cell Biology, vol. 170, no. 6, pp. 993–1004, 2005.
[35]  K. L. Kim, I. S. Shin, J. M. Kim et al., “Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells,” Cardiovascular Research, vol. 72, no. 3, pp. 394–402, 2006.
[36]  G. Fachinger, U. Deutsch, and W. Risau, “Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2,” Oncogene, vol. 18, no. 43, pp. 5948–5953, 1999.
[37]  M. G. Dominguez, V. C. Hughes, L. Pan et al., “Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embyronically because of defects in angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3243–3248, 2007.
[38]  H. Kidoya, M. Ueno, Y. Yamada et al., “Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis,” EMBO Journal, vol. 27, no. 3, pp. 522–534, 2008.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133